- Galapagos NV (NASDAQ:GLPG) and collaboration partner MorphoSys AG (MOR) announce the initiation of a Phase 1 bridging study evaluating a subcutaneous formulation of anti-IL117C antibody MOR106 in patients with moderate-to-severe atopic dermatitis.
- Part 1 of the study will be an open-label dose-ranging trial in healthy volunteers. Part 2 will assess the efficacy of multiple doses against placebo.
- Novartis Pharma AG owns global development and commercialization rights.
- Previously: Galapagos and MorphoSys out-license MOR106 to Novartis for up to $1.1B (July 19)